A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy

ConditionColon Disease
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAalborg University Hospital

About this trial

The trial is about comparing the efficacy of Plenvu with Picoprep. Both are bowel cleansing agents prior to visual examination of the large bowel to exclude cancer disease.

400 patients who are referred for colonoscopy to a single center in North Jutland will be randomised either to Picoprep or Plenvu. These patients will then answer a questionnaire prior to colonoscopy. The questionnaire is about the most common expected side effects and the experience of cleansing og intake of the bowel agents.

The effect of the two agents will examined using a special scoring system (Harefield) to determine the quality of bowel cleansing. Colonoscopist who evaluate the cleansing is blinded to which agent the patient has taken.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Ambulant colonoscopy

Older than18

Disqualifiers

Younger than 18

Known with severe heart failure

Known with severe renal failure (eGFR<30)

Known for colonic stenosis

Trial design

Design model

Parallel

Treatments tested in this trial

  • Picoprep

    Drug

    200 patients will be randomised to this arm

  • Plenvu

    Drug

    200 patients will be randomised to this arm

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: PicoprepActive comparator 1 intervention
Group B: PlenvuExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Efficacy of cleansing agent

The primary endpoint is the efficacy of cleansing preparations measured by the quality of cleansing. This is done using the validated Harefield Cleansing Scale. The cleansing quality is measured after dividing the colon into 5 segments (Rectum, sigmoid colon, Descending colon, Transverse colon, and Ascending colon/Cecum) and each segment is scored from 0 (irremovable heavy hard stool), 1 (Semi-solid, only partially removable stools), 2 (Brown liquid/removable semi-solid stools) 3 (Clear liquid), and 4 (empty and clean), then a total grade is given. Grade A (all segments scored 3 or 4) and B (one or more segments scored 2) are considered as successful cleansing. Grade C (one or more segments scored 1) and D (one or more segments scored 0) is considered unsuccessful cleansing.

Time frame
18 hours

Secondary outcomes

1

Tolerability to the cleansing agent

The secondary endpoint is the tolerability of the patient to cleansing preparation. This is measured using a previously validated tolerability questionnaire.

Time frame
18 hours

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Aalborg University Hospital

Lead sponsor

Regionshospital Nordjylland

Collaborator

Norgine

Collaborator